The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2019 | An MRD discussion: when, who and how
Maria-Victoria Mateos, MD, PhD from University Hospital of Salamanca, Salamanca, Spain, Nikhil Munshi, MD, from Dana-Farber Cancer Institute, Boston, MA and Faith Davies, MBBCh, MRCP, MD, FRCPath, from NYU Langone Medical Center, New York, NY, discuss their views on which patients should undergo measurable residual disease (MRD) testing, at what time points testing should be carried out and how MRD should be tested. This interview took place at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
